New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
07:53 EDTVRSKVerisk Analytics price target raised to $63 from $53 at Susquehanna
Susquehanna raised its price target on Verisk Analytics and believes it will be a good year for the company. The firm expects Property & Casualty to be a tailwind and is its highest margin product. Shares are Positive rated.
News For VRSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
10:37 EDTVRSKBofA/Merrill's Top 10 US Ideas for Q4 2015
Subscribe for More Information
September 30, 2015
19:12 EDTVRSKOn The Fly: After Hours Movers
UP AFTER EARNINGS: 8Point3 Energy (CAFD), up 3.2%. ALSO HIGHER: PBF Energy (PBF), up 4.3% after announcing that it will acquire a Torrance, CA refinery from ExxonMobil (XOM)... Verisk Analytics (VRSK), up 5.2% after being added to the S&P 500. LOWER: Medgenics (MDGN), down 11.1% after filing to sell common stock... Concho Resources (CXO), down 4.4% after filing to sell 7M shares of common stock... Joy Global (JOY), down 2.2% after Verisk Analytics replaced the company in the S&P 500... Amicus Therapeutics (FOLD), down 1.7% after filing to sell 5.92M shares of common stock for holders.
18:07 EDTVRSKS&P announces changes to the S&P 400, 500 indices
S&P 500 constituent Joy Global (JOY) will replace Thoratec (THOR) in the S&P MidCap 400, and Verisk Analytics (VRSK) will replace Joy Global in the S&P 500 after the close of trading on Wednesday, October 7. S&P 500 constituent St. Jude Medical (STJ) is acquiring Thoratec in a deal expected to be completed on or about that date, pending final approvals. Joy Global has a market capitalization more representative of the mid-cap market space.
17:18 EDTVRSKVerisk Analytics to replace Joy Global in S&P 500 as of 10/7 close
Subscribe for More Information
September 23, 2015
12:36 EDTVRSKVerisk Analytics management to meet with SunTrust
Meetings to be held in Texas on September 28-29 hosted by SunTrust.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use